Table 1 Demographic and clinic characteristics of the patients
From: Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
Characteristics | Control (N = 28) | CIMAvaxEGF (N = 12) | P-value |
|---|---|---|---|
Gender | |||
Male | 8 (66.7%) | 18 (64.3%) | 0.92 |
Female | 4 (33.3%) | 10 (35.7%) | |
Age | |||
≤ 60 | 9 (75.0%) | 16 (57.1%) | 0.28 |
> 60 | 3 (25.0%) | 12 (42.5%) | |
Race | |||
White | 16 (57.1%) | 6 (50.0%) | 0.65 |
Afro | 10 (35.7%) | 4 (33.3%) | |
Other | 2 (7.1%) | 2 (16.7%) | |
Smoking History | |||
Current | 17 (60.7%) | 7 (58.3%) | 0.63 |
Pass | 9 (32.8%) | 3 (25.0%) | |
Never | 2 (7.1%) | 2 (16.7%) | |
ECOG | |||
0 | 11 (39.3%) | 5 (41.7%) | 0.29 |
1 | 13 (46.4%) | 3 (25.0%) | |
2 | 4 (14.3%) | 4 (33.3%) | |
Disease stage | |||
IIIb | 13 (46.4%) | 7 (58.3%) | 0.26 |
IV | 15 (53.6%) | 5 (41.7%) | |
Tumor histology | |||
Adenocarcinoma | 7 (25.0%) | 2 (16.7%) | 0.56 |
Squamous | 21 (75.0%) | 10 (83.3%) | |
Response to first Line | |||
Complete response | 2 (7.1%) | 1 (8.3%) | 0.78 |
Partial response | 11 (39.3%) | 6 (50.0%) | |
Stable diseases | 15 (53.6%) | 5 (41.7%) | |